TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.160nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.180nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.180nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.260nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.320nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.380nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.390nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.440nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.780nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.30nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.5nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.5nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.10nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.40nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 3.40nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 4.60nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 6.60nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
Affinity DataIC50: 23nMAssay Description:Antagonist activity at human CCR4 expressed in rat chem-5 cells assessed as inhibition of CCL22-induced calcium flux measured at 2.5 secs time interv...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 25nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 26nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 27nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
Affinity DataIC50: 27nMAssay Description:Antagonist activity at human CCR4 expressed in rat chem-5 cells assessed as inhibition of CCL22-induced calcium flux measured at 2.5 secs time interv...More data for this Ligand-Target Pair
Affinity DataIC50: 32nMAssay Description:Antagonist activity at human CCR4 expressed in rat chem-5 cells assessed as inhibition of CCL22-induced calcium flux measured at 2.5 secs time interv...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 32nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
Affinity DataIC50: 32nMAssay Description:Antagonist activity at human CCR4 expressed in rat chem-5 cells assessed as inhibition of CCL22-induced calcium flux measured at 2.5 secs time interv...More data for this Ligand-Target Pair
Affinity DataIC50: 34nMAssay Description:Antagonist activity at human CCR4 expressed in rat chem-5 cells assessed as inhibition of CCL22-induced calcium flux measured at 2.5 secs time interv...More data for this Ligand-Target Pair
Affinity DataIC50: 36nMAssay Description:Antagonist activity at human CCR4 expressed in rat chem-5 cells assessed as inhibition of CCL22-induced calcium flux measured at 2.5 secs time interv...More data for this Ligand-Target Pair
Affinity DataIC50: 37nMAssay Description:Antagonist activity at human CCR4 expressed in rat chem-5 cells assessed as inhibition of CCL22-induced calcium flux measured at 2.5 secs time interv...More data for this Ligand-Target Pair
Affinity DataIC50: 40nMAssay Description:Antagonist activity at human CCR4 expressed in rat chem-5 cells assessed as inhibition of CCL22-induced calcium flux measured at 2.5 secs time interv...More data for this Ligand-Target Pair
Affinity DataIC50: 41nMAssay Description:Antagonist activity at human CCR4 expressed in rat chem-5 cells assessed as inhibition of CCL22-induced calcium flux measured at 2.5 secs time interv...More data for this Ligand-Target Pair
Affinity DataIC50: 42nMAssay Description:Antagonist activity at human CCR4 expressed in rat chem-5 cells assessed as inhibition of CCL22-induced calcium flux measured at 2.5 secs time interv...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 43nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
Affinity DataIC50: 44nMAssay Description:Antagonist activity at CCR4 in human CCRF-CEM cells assessed as inhibition of CCL22-mediated chemotaxis in presence of 100% human serum pre-incubated...More data for this Ligand-Target Pair
Affinity DataIC50: 47nMAssay Description:Antagonist activity at human CCR4 expressed in rat chem-5 cells assessed as inhibition of CCL22-induced calcium flux measured at 2.5 secs time interv...More data for this Ligand-Target Pair
Affinity DataIC50: 54nMAssay Description:Antagonist activity at human CCR4 expressed in rat chem-5 cells assessed as inhibition of CCL22-induced calcium flux measured at 2.5 secs time interv...More data for this Ligand-Target Pair
Affinity DataIC50: 54nMAssay Description:Antagonist activity at human CCR4 expressed in rat chem-5 cells assessed as inhibition of CCL22-induced calcium flux measured at 2.5 secs time interv...More data for this Ligand-Target Pair
Affinity DataIC50: 58nMAssay Description:Antagonist activity at human CCR4 expressed in rat chem-5 cells assessed as inhibition of CCL22-induced calcium flux measured at 2.5 secs time interv...More data for this Ligand-Target Pair
Affinity DataIC50: 58nMAssay Description:Antagonist activity at CCR4 in human CCRF-CEM cells assessed as inhibition of CCL22-mediated chemotaxis in presence of 100% human serum pre-incubated...More data for this Ligand-Target Pair
Affinity DataIC50: 69nMAssay Description:Antagonist activity at human CCR4 expressed in rat chem-5 cells assessed as inhibition of CCL22-induced calcium flux measured at 2.5 secs time interv...More data for this Ligand-Target Pair
Affinity DataIC50: 70nMAssay Description:Antagonist activity at CCR4 in human CCRF-CEM cells assessed as inhibition of CCL22-mediated chemotaxis in presence of 100% human serum pre-incubated...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 73nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 90nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:To measure binding of 125I-TARC or 125I-MDC to cells expressing CCR4 (e.g., CEM cells (e.g., ATCC HB-12624)), the 125I-TARC or 125I-MDC is diluted to...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:To measure binding of 125I-TARC or 125I-MDC to cells expressing CCR4 (e.g., CEM cells (e.g., ATCC HB-12624)), the 125I-TARC or 125I-MDC is diluted to...More data for this Ligand-Target Pair